PWM
HQL

Perigon Wealth Management’s abrdn Life Sciences Investors HQL Stock Holding History

Perigon Wealth Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,007
Closed -$158K – 730
2020
Q4 		$158K Buy
+8,007
New +$148K 0.02% 447

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
MC
Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Perigon Wealth Management's HQL Position: Q1 2021 in Review

Perigon Wealth Management sold out of abrdn Life Sciences Investors (HQL) in Q1 2021, closing a stake of 8,007 shares — an estimated $158K sold.

Perigon Wealth Management first reported a position in HQL in Q4 2020 and held it in 1 quarter. The position peaked at $158K in Q4 2020. 65 funds tracked by Wall St. Rank hold HQL as of Q1 2021.

  • Perigon Wealth Management reported no remaining abrdn Life Sciences Investors position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 8,007 abrdn Life Sciences Investors shares in Q1 2021, an estimated $158K.
  • Perigon Wealth Management first reported a position in abrdn Life Sciences Investors in Q4 2020 and held it in 1 quarter.
  • Perigon Wealth Management's abrdn Life Sciences Investors position peaked at $158K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.